Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

FDA Approves Ascendis Pharma's Yorvipath (Palopegteriparatide; Developed As TransCon PTH) For Hypoparathyroidism In Adults, Ascendis Is Completing Manufacturing Of Commercial Product For The U.S. Market And Anticipates Initial Supply Will Be Available In Q1 Of 2025

Author: Benzinga Newsdesk | August 12, 2024 07:04am

Posted In: ASND